Disease × agent evidence record

Device for Long COVID: evidence, trials and status

Device has 1 completed trial and 18 linked publications for Long COVID. Completed trials may or may not have posted results; follow the NCT links to check.

1 registered trials 0 recruiting 18 publications Evidence tier C · Preliminary Score 33.5
Research Tracker › Pairs › Long COVID › Device
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Device is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Device to Long COVID: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 88 participants. Registered activity dates to 2023. The literature layer holds 18 publications for this pair: 8 clinical trial publications and 10 other publications. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.

Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.

Open in Repurposing ExplorerAgent page: DeviceLong COVID hubLong COVID biomarkers & interventionsPubChem

Evidence table

Evidence tierC · Preliminary
Evidence score33.5 (trials 2.5, literature 26.0, tier 5, approved bonus 0.0)
Registered trials1 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 0 other
Linked publications18 (10 other publications, 8 clinical trial publications)
Agent typeDevice (Medical Device)
Development stage (any indication)Investigational
Mechanism / classNot recorded
Data sourcesOSMF therapeutic agent database, ClinicalTrials.gov, PubMed
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT05817006Research of the Long-COVID-19 Syndrome in the Children
Samara State Medical University · 2023
completedNot applicable88

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

This is a device or procedure-based intervention; no pharmacological mechanism is recorded.

Clinical notes: Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.

Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.

Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.

Frequently asked questions

Is Device approved for Long COVID?

Device is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Device in clinical trials for Long COVID?

ClinicalTrials.gov lists 1 registered trial linking Device to Long COVID: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 88 participants. Registered activity dates to 2023.

What does the evidence show for Device in Long COVID?

Device has 1 completed trial and 18 linked publications for Long COVID. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.

Cite this page

Open Source Medicine Foundation. Device for Long COVID: evidence, trials and status. OSMF Research Tracker. Updated 2026-10-07. https://research.opensourcemed.info/pairs/long-covid/device.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.